Furthermore, another main gene that showed regulation upon Bz therapy was CSF2, and studies have not explored yet the production of CSF2 after Bz treatment, but CSF1 when used as a therapy for CCC in mice, induced a mixed Treg/Th1/Th2 immune response that contributed to a persistent cardiac inflammation (González et al., 2013), implying that the role of CSF2 deserves to be further investigated. The gene discussed is CSF1; the disease is inflammatory response.